Long-awaited results from the START study show that people with HIV who start antiretroviral therapy (ART) soon after diagnosis, while their CD4 T-cell count is still high, have a lower risk of illness and death than those who wait, according to a May 27 announcement from the National Institute of Allergy and Infectious Diseases.
HIVandHepatitis.com coverage of the 50th European Association for the Study of the Liver International Liver Congress (EASL 2015) in Vienna, April 22-26, 2015.
Conference highlights include interferon-free hepatitis C treatment for people with advanced disease, experimental HCV antivirals, hepatitis B and delta, and management of liver disease complications.
The European Association for the Study of the Liver (EASL) released its latest hepatitis C treatment guidelines at the 50th International Liver Congress taking place this week in Vienna. The guidelines recommend a variety of interferon-free direct-acting antiviral (DAA) regimens for people with hepatitis C virus genotypes 1-6. The panel offered recommendations for patient groups that remain difficult to treat, such as those with decompensated cirrhosis, but noted that more research is still needed in several areas. Also concurrent with the conference, EASL and the Latin American Association for the Study of the Liver released joint guidelines for non-invasive assessment of liver disease severity, noting that liver stiffness measurement is becoming the standard of care.
HIVandHepatitis.com coverage of the 2015 Conference on Retroviruses and Opportunistic infections (CROI 2015), February 23-26, 2015, in Seattle.
Conference highlights include PrEP and HIV treatment as prevention, hepatitis C treatment for HIV/HCV coinfected people, new antiretroviral drugs, HIV cure research, HIV-related conditions, TB, Ebola virus, and access to care.